Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 04 March 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration's (FDA) sprawling White Oak campus will soon absorb one of the agency's largest main regulatory divisions, it has announced
The White Oak campus, located in Silver Spring, MD, is meant to consolidate all of FDA's headquarter operations in one place. Previously, FDA has offices throughout the Washington, DC metro area, making it difficult for different divisions of FDA to meet with one another in person.
Starting in May 2014, FDA's Center for Biologics Evaluation and Research (CBER) is set to join the growing campus. The center is presently split between multiple locations in the Maryland cities of Rockville and Bethesda.
The move, announced in a Federal Register announcement on 4 March 2014, will take approximately eight weeks to complete.
The move will also have implications for members of the biotechnology industry. While the move will have no effect on CBER's electronic submissions gateway (ESG), all paper-based applications will need to be sent to its new mailing address at White Oak.
The move could also affect review time frames, though FDA said it will be making "every effort" to meet its user fee deadlines and minimize any delays due to the move.
"Should delays affecting receipt and review of applications and other submissions occur, we intend to update the FDA website as needed," FDA wrote.
CBER's collection of lot samples may be impacted the most by its move. "Because of the relocation of CBER's Sample Custodian … CBER will not be able to receive lot release samples during the 2 weeks surrounding this personnel move," it said. Industry will therefore need to release samples to CBER either before the move, or wait until its sample custodian is able to set up a new office.
Information about the move will be made available online on FDA's website.
Federal Register Notice
Tags: White Oak, Biologics
Regulatory Focus newsletters
All the biggest regulatory news and happenings.